Teva Pharmaceutical Industries Ltd
TASE:TEVA

Watchlist Manager
Teva Pharmaceutical Industries Ltd Logo
Teva Pharmaceutical Industries Ltd
TASE:TEVA
Watchlist
Price: 9 699 ILS -2.81%
Market Cap: 109.2B ILS

ROE

3.4%
Current
Improving
by 7.3%
vs 3-y average of -3.9%

Return on Equity (ROE) measures how effectively a company generates profit from shareholders` equity. It shows how much net income is earned for each dollar invested by shareholders.

ROE
3.4%
=
Net Income
$712m
/
Avg Total Equity
$6.7B

Return on Equity (ROE) measures how effectively a company generates profit from shareholders` equity. It shows how much net income is earned for each dollar invested by shareholders.

ROE
3.4%
=
Net Income
₪712m
/
Avg Total Equity
$6.7B

Peer Comparison

Country Company Market Cap ROE
IL
Teva Pharmaceutical Industries Ltd
TASE:TEVA
111.6B ILS
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
ZA
Aspen Pharmacare Holdings Ltd
JSE:APN
51.8B Zac
Loading...
US
Eli Lilly and Co
NYSE:LLY
982.2B USD
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
526.1B USD
Loading...
CH
Roche Holding AG
SIX:ROG
273.2B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210.7B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219.9B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
270.7B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
No Stocks Found

Market Distribution

In line with most companies in Israel
Percentile
39th
Based on 630 companies
39th percentile
3.4%
Low
-1 191.7% — 0.2%
Typical Range
0.2% — 13.6%
High
13.6% — 3 162.7%
Distribution Statistics
Israel
Min -1 191.7%
30th Percentile 0.2%
Median 6.5%
70th Percentile 13.6%
Max 3 162.7%

Teva Pharmaceutical Industries Ltd
Glance View

Teva Pharmaceutical Industries Ltd., a titan in the global pharmaceutical landscape, has navigated the intricate world of pharmaceuticals with a blend of strategic vision and operational efficiency. Founded in 1901 and headquartered in Israel, Teva has become synonymous with the production of affordable generic medications, a key pillar of its business model. The company's narrative is one of adaptability and foresight, having positioned itself as a leader in the generic drug sector by leveraging economies of scale and a vast distribution network. By acquiring and integrating smaller pharmaceutical firms over the years, Teva has expanded its portfolio to include a vast array of treatments that address a broad spectrum of therapeutic areas. This strategic expansion has enabled the company to offer nearly the same efficacy as brand-name drugs at a fraction of the cost, thus capturing significant market share and delivering value to both patients and healthcare systems worldwide. Beyond its prowess in generics, Teva has carved a niche in the specialty medicines market, focusing on innovative therapies that address complex conditions such as multiple sclerosis, migraine, and movement disorders. This dual-track approach to growth allows Teva to balance the volume-driven nature of the generics market with the higher margins offered by specialty drugs. The synthesis of these two facets – comprehensive generic offerings and targeted specialty pharmaceuticals – underpins Teva's revenue streams. Through a combination of robust pipeline development, strategic partnerships, and a commitment to operational excellence, Teva navigates the challenges of a competitive industry marked by ever-evolving regulations and pricing pressures, striving to maintain its status as a reliable provider of healthcare solutions on a global scale.

TEVA Intrinsic Value
5 200.75 ILS
Overvaluation 46%
Intrinsic Value
Price
What is Return on Equity?
Return on Equity (ROE) measures how effectively a company generates profit from shareholders` equity. It shows how much net income is earned for each dollar invested by shareholders.
How is ROE calculated?

ROE is calculated by dividing the Net Income by the Avg Total Equity.

ROE
3.4%
=
Net Income
$712m
/
Avg Total Equity
$6.7B
What is Teva Pharmaceutical Industries Ltd's current ROE?

The current ROE for Teva Pharmaceutical Industries Ltd is 3.4%, which is above its 3-year median of -3.9%.

How has ROE changed over time?

Over the last 3 years, Teva Pharmaceutical Industries Ltd’s ROE has increased from -3.8% to 3.4%. During this period, it reached a low of -7.6% on Dec 31, 2022 and a high of 3.2% on Sep 30, 2025.

Back to Top